Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio, ZAI Lab - LARVOL DELTA

Comparing Ravulizumab versus Efgartigimod in improving functional scales among AChR-AB positive generalized myasthenia Gravis patients (ACTRIMS Forum 2026) - "Although there is some evidence that efgartigimod provides rapid improvement, there is no difference among the medications in the longer duration. A further head-to-head trial is needed with a longer duration."

Clinical • CNS Disorders • Myasthenia Gravis

Efgartigimod as an Add-on Therapy for Anti-IgLON5 Disease: A Case Report. (PubMed, Neurol Ther) - "The patient failed to improve with intravenous immunoglobulin at the outside hospital; similarly, high-dose intravenous methylprednisolone at our institution yielded no clear benefit. To our knowledge, this is the first case report on efgartigimod for treating anti-IgLON5 disease. As an adjuvant therapy, efgartigimod demonstrated promising efficacy, suggesting its potential as a treatment option, especially in patients with limited response to conventional immunotherapy."

Journal • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder

Update on diagnostic and therapeutic strategies for antibody-mediated rejection in kidney transplantation. (PubMed, World J Transplant) - "Ongoing clinical trials evaluating high-dose intravenous immunoglobulin, efgartigimod, fostamatinib, and other novel therapies aim to expand treatment options. These developments highlight the need for well-designed clinical trials to validate biomarkers and therapies and to improve long-term outcomes for kidney transplant recipients."

IO biomarker • Journal • Review • Antibody-mediated Rejection • Inflammation • Transplant Rejection • Transplantation

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus. (PubMed, Front Neurol) - "Real-world use encompassed diverse clinical scenarios and required individualized retreatment decisions and ongoing reassessment. These findings highlight the role of FcRn blockade as a flexible therapeutic option that complements established therapy in everyday care."

Clinical • Journal • Real-world evidence • CNS Disorders • Myasthenia Gravis

C36 - Updates in Diagnostics and Management of Small Fiber Neuropathy (AAN 2026) - "Learning Objectives Participants should become familiar with small fiber neuropathy (SFN) (patho)physiology and its presentation; SFN-specific questionnaires for use in clinic and for the trial; the workup for SFN and indications for EMG, skin biopsies, autonomic studies, corneal confluence microscopy, and laboratory studies; novel immune SFN biomarkers; dthe role of genetic therapies and other novel anti-amyloid treatments in hereditary SFN; the role of immunotherapy in immune SFN- steroids, IVIG, Plasmapheresis; if there is a role to Rituxan, Efgartigimod, or other agents in Immune SFN; results of multiple open label studies supporting the use of IVIG in immune SFN, and some randomized trials; and ongoing randomized controlled Immune SFN-IVIG study background and rationale, inclusion/exclusion criteria, and schedule of events Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student, Coordinator..."

IO biomarker • Gene Therapies • Pain

Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy. (PubMed, Front Immunol) - "Prior treatments included corticosteroids, maintenance intravenous immunoglobulin, mycophenolate mofetil, and rituximab in one patient, and corticosteroids plus maintenance intravenous immunoglobulin in the other. Efgartigimod was generally well tolerated, and some clinical improvements were observed in this population. However, given the small sample size, these findings should be considered preliminary and require confirmation in larger, prospective studies."

Journal • Infectious Disease • Pain • Pediatrics • Respiratory Diseases

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report. (PubMed, Front Immunol) - "This approach quickly improved symptoms, achieved minimal symptom expression (MSE), and allowed faster tapering of corticosteroids and pyridostigmine. While multiple studies have demonstrated the efficacy and safety of efgartigimod, large-scale studies remain necessary to further evaluate the feasibility of combination therapy with rituximab in MuSK-Ab-positive MG."

Journal • CNS Disorders • Immunology • Myasthenia Gravis

Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. (PubMed, Adv Ther) - "Efgartigimod has been recognised as a valuable option for gMG AChR+ treatment in Spain by a multidisciplinary panel of experts through the application of MCDA, receiving higher scores compared with ravulizumab, zilucoplan, and rozanolixizumab."

Journal • CNS Disorders • Immunology • Myasthenia Gravis • Rare Diseases

Evaluating Efficacy and Safety of Efgartigimod versus IVIG in Myasthenia Gravis Exacerbation for Rapid Clinical Response (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University

New trial • CNS Disorders • Myasthenia Gravis

Industry Therapeutic Update from argenx (AAN 2026) - "Sponsored by argenx. Learning Objectives MG ITU- In this MG-focused symposium, we are looking to educate HCPs on the burden associated with early, untreated disease for MG.The objectives include:- Improve awareness of myasthenia gravis, highlighting the burden of disease, impact of misdiagnosis/missed diagnoses and clinical pearls to help ensure a prompt diagnosis- Explore the role of FcRn blockade in myasthenia gravis, differentiating efgartigimod from other agents in the treatment area- Share data supporting the benefit of early intervention in the disease course of myasthenia gravis, including the early use of efgartigimod"

CNS Disorders • Myasthenia Gravis

Industry Therapeutic Update from argenx: Pushing boundaries in CIDP: Pioneering innovations for patient care (AAN 2026) - "Sponsored by argenx. Learning Objectives CIDP ITU- In this CIDP-focused symposium, we are looking to educate HCPs current and future management of CIDP.Objectives will include:-Exploring the lived experience and clinical burden of CIDP from the patient perspective, highlighting unmet needs and anchoring scientific content-Understanding the complex and heterogeneous pathophysiology of CIDP and the rationale for FcRn blockade and complement inhibition-Discussing current therapies, biomarkers, and ongoing clinical trials for efgartigimod alfa and empasiprubart in CIDP"

Clinical

Efgartigimod for steroid-resistant autoimmune glial fibrillary acidic protein astrocytopathy: a case report and literature review. (PubMed, J Neuroimmunol) - "This rare case indicates that efgartigimod is a promising treatment option for steroid-unresponsive GFAP-A."

Journal • CNS Disorders • Immunology • Myasthenia Gravis • GFAP

Add-on efgartigimod in myasthenic crisis: a promising treatment option. (PubMed, Front Neurol) - "Additionally, three patients with MC who only received high-dose efgartigimod treatment all achieved favorable treatment outcomes. This suggests that efgartigimod may serve as an alternative option for MC patients or as a rescue treatment option for refractory individuals."

Journal • CNS Disorders • Critical care • Myasthenia Gravis

Influence of Efgartigimod on Curative Efficacy and Inflammation Factors of Patients with Long Segmental Myelitis. (PubMed, J Vis Exp) - "Efgartigimod lowered serum concentrations of IL-6, IL-41, and IL-10 in LETM patients. The levels of IL-6, IL-41, and IL-10 correlated with EDSS scores, indicating their potential as predictive biomarkers for disease severity and treatment efficacy in LETM."

Journal • Retrospective data • CNS Disorders • Inflammation • IL10 • IL6

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. (PubMed, Ther Adv Neurol Disord) - "In this study, people who received efgartigimod had stable or improving symptoms for up to 48 weeks, while more people who received a placebo had worsening strength, disability, and quality of life. Subcutaneous injections of efgartigimod may offer a more convenient option for people with CIDP compared with current treatments."

Journal • Review • Immunology • Pain

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies. (PubMed, Neurotherapeutics) - "Among 29 patients on prednisone, 58.6 % achieved a significant dose reduction (30.9-16.8 mg/day, p = 0.001), with shorter disease duration predicting successful tapering. Bridging therapy was successful in 5 patients, particularly those receiving azathioprine or mycophenolate (p = 0.040), supporting its utility during transitions to slower-acting immunosuppressants...Overall, efgartigimod was effective and well tolerated, but treatment responses varied, and cycle-based regimens frequently failed to sustain benefit. The observed steroid-sparing effect and predictors of response highlight the need for personalized treatment strategies and prospective studies to refine long-term use and optimize patient selection."

Heterogeneity • Journal • Real-world evidence • CNS Disorders • Myasthenia Gravis

Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety. (PubMed, Curr Neuropharmacol) - "Efgartigimod is associated with clinical benefit in patients with VLOGMG, allowing corticosteroid reduction without compromising comorbidity stability. Early initiation may enable faster disease control and more durable responses."

Journal • Real-world evidence • CNS Disorders • Myasthenia Gravis

Case Report: Guillain-Barré syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment. (PubMed, Front Immunol) - "Here, we report a case of GBS temporally associated with levofloxacin exposure that improved after initiation of efgartigimod, following limited response to plasma exchange, methylprednisolone, and intravenous immunoglobulin. However, this single case cannot establish efficacy, and delayed responses to prior therapies or spontaneous recovery remain possible alternative explanations. Further studies with larger cohorts are needed to clarify the mechanisms underlying this therapy."

Journal • Pain

Efgartigimod for Fetal Acetylcholine Receptor Antibody-Related Disorder. (PubMed, N Engl J Med) - No abstract available

Journal

Efgartigimod for acute NMOSD relapse: rapid IgG clearance and motor recovery in an elderly patient with insufficient response to initial corticosteroid therapy. (PubMed, Neurol Sci) - No abstract available

Journal • Neuromyelitis Optica Spectrum Disorder

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study). (PubMed, Front Med (Lausanne)) - "The findings are expected to provide future treatment strategies to address the major unmet need regarding dryness-related burden in this patient population. Japan Registry of Clinical Trials (jRCT2071250042); registered on 08 July 2025, https://jrct.mhlw.go.jp/en-latest-detail/jRCT2071250042."

Clinical • Journal • P2 data • Fatigue • Immunology • Sjogren's Syndrome • Xerostomia

Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report. (PubMed, Neurologist) - "This case report hints the potential of complement inhibitors as viable treatments alternative for MC patients who poorly respond to antibody-clearing therapy. Besides, further research is necessary to determine the preferred or suitable treatment option for specific patients."

Journal • CNS Disorders • Myasthenia Gravis

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: argenx | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: argenx | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

Immunotherapies in chronic immune-mediated neuropathies. (PubMed, Handb Clin Neurol) - "Among the latter, efgartigimod has recently been approved for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Also rituximab, an anti-CD20 monoclonal antibody mostly used in antimyelin-associated glycoprotein (MAG) antibody neuropathy and in autoimmune nodo-paranodopathies, has been tested both in open and double-blind studies in CIDP, whereas ARGX-117, an antibody targeting the C2 fraction of the complement, is under investigation in multifocal motor neuropathy. In anti-MAG antibody neuropathy, Bruton's tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, are currently tested either as a single agent or in combination with rituximab."

Journal • Review • Complement-mediated Rare Disorders • Immunology • Pain